AlphaYou
Overview
Key stats
Fundamentals Sep 9- Open
- $18.21
- 52-wk high
- $29.23
- High
- $18.32
- 52-wk low
- $12.07
- Low
- $17.24
- Prev close
- $17.28
- Mkt cap
- $13.79B
- Volume
- 4.73M
- Fwd P/E
- 3.7x
- Beta
- -1.24
- P/S
- 3891.3x
- P/B
- 22.3x
- Profit margin
- +0.0%
- Op margin
- +0.0%
- ROE
- -192.5%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsSmart money
8 funds hold a position and insiders have been net buying.
What funds are doing
6 moves · 6 mo
Buys/Adds$140.2MSells/Trims$34.9M
Activist stakes, short interest & more
3 items
Earnings
Earnings came in 7.7% below what analysts expected.
Earnings per share
-$0.28-7.7%
-$0.26 expected
Reports Oct 19, 2026, in 39 days
EPS expected
-$0.21
-$0.31 to -$0.14
Revenue expected
$53.1K
14 analysts
Last 30 days
3up0down
Analysts raising estimates
Financials
What it sold, what it cost, what was left.
Sep 2025Jun 2026
| USD | Sep 2025 | Jun 2026 |
|---|---|---|
| What came in | ||
| Revenue | $0 | $0 |
| What it spent | ||
| Research and development | $131.1M | $157.7M |
| Sales and admin | $103.1M | $62.8M |
| Total operating expenses | $234.2M | $220.5M |
| What was left | ||
| Operating profit | -$234.2M | -$220.5M |
| Interest on debt | $0 | — |
| Profit before tax | -$231.8M | -$215.7M |
| Net profit | -$231.8M | -$215.7M |
| EBITDA | — | -$215.7M |
Technicals
Price structure
This stock is in a strong uptrend, and looks overbought after a fast run-up.
Trend
Strong uptrend
85 / 100
RSI 14
75overbought
20D volatility
85%annualized
52-week range
$12.07$29.23
20D support
$12.07recent floor
20D resistance
$18.32recent ceiling
Returns
5D +23.9%20D +16.0%60D +25.2%
Price vs moving averages
SMA20 +22.2%SMA50 +22.3%SMA200 +6.8%
Volume pace
1.75xvs prior 20D
News
What the news says
3 articles · 7 days
Coverage is bullish
Tone of tracked coverage
Summit Therapeutics shares gain after Jefferies upgrades stock to Buy
BullishSep 9Summit Therapeutics (SMMT) Soars 28% on Ivonescimab Progress
BullishSep 6Summit Therapeutics Shares Rise After Bernstein SocGen Upgrade
Leans bullishAug 28